Is major pathologic response sufficient to predict survival in resectable nonsmall‐cell lung cancer patients receiving neoadjuvant chemotherapy?

BACKGROUND: Major pathologic response (MPR) is mainly focused on residual viable tumor in the tumor bed regardless of lymph node. Herein, we investigated the predictive value of MPR and node status on survival in nonsmall‐cell lung cancer (NSCLC) patients receiving neoadjuvant chemotherapy (NAC) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Cai, Jing‐Sheng, Li, Shuo, Yan, Shu‐Mei, Yang, Jie, Yang, Mu‐Zi, Xie, Chu‐Long, Li, Ji‐Bin, Feng, Yan‐Fen, Yang, Hao‐Xian, Hou, Xue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088941/
https://www.ncbi.nlm.nih.gov/pubmed/33751832
http://dx.doi.org/10.1111/1759-7714.13903

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8088941/
https://www.ncbi.nlm.nih.gov/pubmed/33751832
http://dx.doi.org/10.1111/1759-7714.13903

Ejemplares similares